Cargando…
Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome
Background: Nonalcoholic fatty liver disease (NAFLD) is regarded as a component of metabolic syndrome, which involves insulin resistance (IR) as the primary physiopathological event. The aim of this study was to establish the association between IR, assessed using the triglyceride and glucose index...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181222/ https://www.ncbi.nlm.nih.gov/pubmed/35683431 http://dx.doi.org/10.3390/jcm11113043 |
_version_ | 1784723716440064000 |
---|---|
author | Amzolini, Anca Maria Forțofoiu, Mircea-Cătălin Alhija, Anca Barău Vladu, Ionela Mihaela Clenciu, Diana Mitrea, Adina Forțofoiu, Maria Matei, Daniela Diaconu, Magdalena Tudor, Marinela Sinziana Micu, Elena Simona |
author_facet | Amzolini, Anca Maria Forțofoiu, Mircea-Cătălin Alhija, Anca Barău Vladu, Ionela Mihaela Clenciu, Diana Mitrea, Adina Forțofoiu, Maria Matei, Daniela Diaconu, Magdalena Tudor, Marinela Sinziana Micu, Elena Simona |
author_sort | Amzolini, Anca Maria |
collection | PubMed |
description | Background: Nonalcoholic fatty liver disease (NAFLD) is regarded as a component of metabolic syndrome, which involves insulin resistance (IR) as the primary physiopathological event. The aim of this study was to establish the association between IR, assessed using the triglyceride and glucose index (TyG), and histopathological features of NAFLD lesions. Methods: The study included 113 patients with metabolic syndrome. Fasting plasma glucose (FPG), fasting lipid profiles and liver enzymes were measured. IR was assessed by the TyG index. Liver biopsy was performed for assessment steatosis and fibrosis. Results: the TyG index had a mean value of 8.93 ± 1.45, with a higher value in the patients with overweight (p = 0.002) and obesity (p = 0.004) characteristics than in the patients with normal weight. The TyG index mean value was 8.78 ± 0.65 in subjects without NASH, 8.91 ± 0.57 in patients with borderline NASH and 9.13 ± 0.55 in patients with definite NASH. A significant difference was found between subjects without NASH and the ones with definite NASH (p = 0.004), as well as in patients with early fibrosis vs. those with significant fibrosis. The analysis of the area under the ROC curve proved that the TyG index is a predictor of NASH (p = 0.043). Conclusion: the TyG index is a facile tool that can be used to identify individuals at risk for NAFLD. |
format | Online Article Text |
id | pubmed-9181222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91812222022-06-10 Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome Amzolini, Anca Maria Forțofoiu, Mircea-Cătălin Alhija, Anca Barău Vladu, Ionela Mihaela Clenciu, Diana Mitrea, Adina Forțofoiu, Maria Matei, Daniela Diaconu, Magdalena Tudor, Marinela Sinziana Micu, Elena Simona J Clin Med Article Background: Nonalcoholic fatty liver disease (NAFLD) is regarded as a component of metabolic syndrome, which involves insulin resistance (IR) as the primary physiopathological event. The aim of this study was to establish the association between IR, assessed using the triglyceride and glucose index (TyG), and histopathological features of NAFLD lesions. Methods: The study included 113 patients with metabolic syndrome. Fasting plasma glucose (FPG), fasting lipid profiles and liver enzymes were measured. IR was assessed by the TyG index. Liver biopsy was performed for assessment steatosis and fibrosis. Results: the TyG index had a mean value of 8.93 ± 1.45, with a higher value in the patients with overweight (p = 0.002) and obesity (p = 0.004) characteristics than in the patients with normal weight. The TyG index mean value was 8.78 ± 0.65 in subjects without NASH, 8.91 ± 0.57 in patients with borderline NASH and 9.13 ± 0.55 in patients with definite NASH. A significant difference was found between subjects without NASH and the ones with definite NASH (p = 0.004), as well as in patients with early fibrosis vs. those with significant fibrosis. The analysis of the area under the ROC curve proved that the TyG index is a predictor of NASH (p = 0.043). Conclusion: the TyG index is a facile tool that can be used to identify individuals at risk for NAFLD. MDPI 2022-05-28 /pmc/articles/PMC9181222/ /pubmed/35683431 http://dx.doi.org/10.3390/jcm11113043 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Amzolini, Anca Maria Forțofoiu, Mircea-Cătălin Alhija, Anca Barău Vladu, Ionela Mihaela Clenciu, Diana Mitrea, Adina Forțofoiu, Maria Matei, Daniela Diaconu, Magdalena Tudor, Marinela Sinziana Micu, Elena Simona Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome |
title | Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome |
title_full | Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome |
title_fullStr | Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome |
title_full_unstemmed | Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome |
title_short | Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome |
title_sort | triglyceride and glucose index as a screening tool for nonalcoholic liver disease in patients with metabolic syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181222/ https://www.ncbi.nlm.nih.gov/pubmed/35683431 http://dx.doi.org/10.3390/jcm11113043 |
work_keys_str_mv | AT amzoliniancamaria triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT fortofoiumirceacatalin triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT alhijaancabarau triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT vladuionelamihaela triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT clenciudiana triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT mitreaadina triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT fortofoiumaria triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT mateidaniela triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT diaconumagdalena triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT tudormarinelasinziana triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome AT micuelenasimona triglycerideandglucoseindexasascreeningtoolfornonalcoholicliverdiseaseinpatientswithmetabolicsyndrome |